MedTrace Logo

Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers

NCT01156246 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-06-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether treatment with a fixed dose combination dapagliflozin/metformin tablet is affected by food.

Conditions

  • Healthy

Interventions

DRUG

Dapagliflozin/Metformin

oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.

Sponsors & Collaborators

Principal Investigators

  • Aslak Rautio · Quintiles Hermelinen AB, Varvsgatan 53, SE-972 33 Luleå, Sweden

  • Wolfgang Kühn · Quintiles AB, Global Phase I Services, Strandbodgatan 1, SE-753 23 Uppsala, Sweden

  • Mirjana Kujacic · AZ Global Clinical Development, Pepparedsleden 1, 431 83 Mölndal, 431 83 Mölndal

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01156246 on ClinicalTrials.gov